MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process

被引：34
|
作者：
Dong, Ying [1 ]
Jin, Xintian [2 ]
Sun, Zhiqiang [3 ]
Zhao, Yueming [4 ]
Song, Xianjing [5 ]
机构：
[1] Tumor Hosp Jilin Prov, Dept Radiotherapy, Changchun 130021, Peoples R China
[2] Tumor Hosp Jilin Prov, Dept Thorac, Changchun 130021, Peoples R China
[3] Tumor Hosp Jilin Prov, Dept Invas Technol, Changchun 130021, Peoples R China
[4] Tumor Hosp Jilin Prov, Dept Oncol, Changchun 130021, Peoples R China
[5] Jilin Univ, Hosp 2, Dept Cardiol, Changchun 130041, Peoples R China
来源：
MOLECULES AND CELLS | 2017年 / 40卷 / 03期
关键词：
cdc42; EMT; migration; MiR-186; NSCLC; CELL-PROLIFERATION; 3RD-LINE TREATMENT; CANCER; EXPRESSION; MICRORNAS; INVASION; MIR-B-10;
D O I：
10.14348/molcells.2017.2291
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
In this study, qRT-PCR was employed to identify that miR-186 expression level in NSCLC tissues are highly associated with lymph node metastasis. In addition, through the application of western blotting, luciferase assay and qRT-PCR, it was found that miR-186 targeted 3. UTR of cdc42 mRNA and down-regulated cdc42 protein level in a post-transcriptional manner. Transwell assay indicated that cdc42 partially reversed the effect of miR-186 mimics. Besides, miR-186 was proved to regulate EMT by influencing biomarkers of this process and cell adhesion ability. Thus, miR-186 is a potential target for NSCLC therapy. miR-186 is proposed to be one of tumor-suppressors and may serve as a therapeutic target in NSCLC treatment.
引用
收藏
页码：195 / 201
页数：7
相关论文
共 50 条
  • [1] miR-186 Represses Proliferation, Migration, Invasion, and EMT of Hepatocellular Carcinoma via Directly Targeting CDK6
    Lu, Junfeng
    Zhao, Zhongsong
    Ma, Yanhong
    ONCOLOGY RESEARCH, 2020, 28 (05) : 509 - 518
  • [2] miR-185 inhibits cell migration and invasion of hepatocellular carcinoma through CDC42
    Zhang, Qingjun
    Chen, Yun
    Liu, Ke
    ONCOLOGY LETTERS, 2018, 16 (03) : 3101 - 3107
  • [3] MicroRNA-384 inhibits proliferation migration and invasion of glioma by targeting at CDC42
    Gu, Gengshi
    Wang, Li
    Zhang, Junchen
    Wang, Hao
    Tan, Tan
    Zhang, Guangning
    ONCOTARGETS AND THERAPY, 2018, 11 : 4075 - 4085
  • [4] miR-195 inhibits esophageal cancer cell proliferation via targeting cyclin D1 and Cdc42
    Huang, Chen
    Chen, Qianshun
    Xu, Xunyu
    Wu, Xu
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 120
  • [5] MiR-29a inhibits cell proliferation and migration by targeting the CDC42/PAK1 signaling pathway in cervical cancer
    Chen, Rong
    Zhang, Lu
    ANTI-CANCER DRUGS, 2019, 30 (06) : 579 - 587
  • [6] miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma
    Mao, Fengxia
    Zhang, Ju
    Cheng, Xinru
    Xu, Qianya
    CANCER CELL INTERNATIONAL, 2019, 19 (01)
  • [7] MiR-22-3p suppresses NSCLC cell migration and EMT via targeting RAC1 expression
    Wang, Xuejiao
    Wang, Xiaobin
    Jiang, Tao
    Zhang, Zhipei
    Xie, Nianlin
    Yang, Guang
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2023, 23 (03)
  • [8] MicroRNA-224 Suppresses Colorectal Cancer Cell Migration by Targeting Cdc42
    Ke, Tao-Wei
    Hsu, Han-Lin
    Wu, Yu-Hua
    Chen, William Tzu-Liang
    Cheng, Ya-Wen
    Cheng, Chao-Wen
    DISEASE MARKERS, 2014, 2014
  • [9] MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation
    Liu, L.
    Wang, Y.
    Bai, R.
    Yang, K.
    Tian, Z.
    ONCOGENESIS, 2016, 5 : e224 - e224
  • [10] LncRNA HCP5 enhances the proliferation and migration of cervical cancer via miR-216a-5p/CDC42 axis
    Li, Xiaomin
    Chen, Bingxin
    Huang, Anni
    Ren, Ci
    Wang, Liming
    Zhu, Tong
    Xiong, Jinfeng
    Ding, Wencheng
    Wang, Hui
    JOURNAL OF CANCER, 2022, 13 (05): : 1882 - 1894
12345